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According to the Barker hypothesis, the period of pregnancy and the intrauterine environment are crucial to the
tendency to develop diseases like hypertension, diabetes, coronary heart disease, metabolic disorders, pulmonary, renal
and mental illnesses. The external environment affects the development of a particular phenotype suitable for an
environment with characteristics that closely resemble intrauterine conditions. If the extra-uterine environment differs
greatly from the intra-uterine one, the fetus is more prone to develop disease. Subsequent studies have shown that
maternal diseases like depression and anxiety, epilepsy, asthma, anemia and metabolic disorders, like diabetes, are able
to determine alterations in growth and fetal development. Similarly, the maternal lifestyle, particularly diet, exercise and
smoking during pregnancy, have an important role in determining the risk to develop diseases that manifest
themselves both during childhood and particularly in adulthood. Finally, there are abundant potential sources of
pollutants, both indoor and outdoor, in the environment in which the child lives, which can contribute to an increased
probability to the development of several diseases and that in some cases could be easily avoided.
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Several epidemiological studies have revealed that expos-
ure to an unfavourable environment in early life is asso-
ciated with a significantly increased risk of later disease,
a phenomenon termed ‘early life programming’. Factors
that adversely affect the gestational and early postnatal
environment such as maternal diseases and their treat-
ments, life-style such as nutrition and activity as well as
exposure to pollutants can alter fetal development with
persistent effects on health.
Major maternal causal diseases include psychiatric-
neurologic disorders, diabetes, asthma, sleep related
breathing disorders, and anemia. Furthermore, an in-
creasing body of proof highlights the weight of a
mother’s nutrition and of micro-nutrients, and life-style
as well as exposure to pollutants, from preconception* Correspondence: l.capra@ospfe.it
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reproduction in any medium, provided the orthrough lactation, in programming the emerging organ
systems and homeostatic pathways of her offspring.
Moreover, exposure of the developing embryo or fetus
to some environmental agents like gamma irradiation
and thalidomide is well known to produce anatomical
anomalies leading to in utero death or structural birth
defects, commonly termed teratogenesis. Perhaps less
well appreciated is that such environmental exposures
also can cause functional disorders that persist postna-
tally and into adult life. This seems to be true also for
hormones that when present in non-physiological con-
centrations during ‘critical periods’ of perinatal life can
act as ‘endogenous functional teratogens’. For example
perinatal hyperinsulinism, pathognomonic in the off-
spring of diabetic mothers, may lead to ‘malprogram-
ming’ of neuroendocrine systems regulating body
weight, food intake and metabolism. This results in an
increased disposition to become obese and to develop
diabetes throughout life [1]. However, the spectrum of
such postnatal consequences is growing, and moretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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system, brain function, and cancer, to name a few.
Many human teratogens elicit their deleterious effects
through mechanisms involving the generation of reactive
oxygen species (ROS) and oxidative stress [2]. Since
many antioxidant regulation enzymes are not well
expressed early in organogenesis, it may explain why
embryos, in earlier periods of development, are more
susceptible to teratogen-induced dysmorphogenesis and
functional teratogenesis.
Maternal diseases during pregnancy
Maternal anxiety, depression and selective inhibitors of
serotonin re-uptake inhibitors (SSRIs)
Over 13% of women experience episodes of depression
during pregnancy or during the first year after the deliv-
ery and up to 18% of women develop anxiety syndromes
[3]. This reflects on fetal development in different ways.
Maternal depression during pregnancy increases the risk
of delivering a baby of low birth weight but with a cen-
tral distribution of adipose tissue, while post-partum de-
pression is associated with an overall increase in fetal
adipose tissue [4]. Depression in pregnancy influences
the development of the hypothalamic-pituitary-adrenal
axis by exposing it to higher concentrations of cortico-
trophin releasing hormone (CRH) which are related with
lower body mass index (BMI) and higher central adipos-
ity in the child [5]. Post-partum depression is associated
with a reduction in breast feeding, which is a protective
feature against the development of obesity; and a risk
factor for unhealthy maternal behaviours like overeating
and little exercise, that are behaviours inevitably trans-
mitted to the child.
Moreover, children of mothers with high levels of
anxiety-depressive disorders at 32nd week of gestation,
have almost twice the risk (RR = 1.68) of developing
asthma by the age of seven and a half years [6]. Never-
theless, exposure to maternal depression and anxiety
restricted to the first year of life, has only a limited asso-
ciation with successive asthma (RR = 1.25) [7].
Another aspect that must be considered is the influ-
ence of maternal psychiatric disorders on the develop-
ment and morphology of the fetal brain. Children whose
mothers suffer from anxiety-depressive syndrome have
less developed areas of the brain responsible for control-
ling cognitive functions, particularly the prefrontal cor-
tex, the structure that regulates the schedule of action,
reasoning, working memory, attention and some aspects
of language [1]. Consequently the baby is exposed to an
increased risk of a tendency to develop a less optimal
mother-child interaction and insecure infant attachment
[8] and having problem behaviours and lower competen-
cies particularly in boys [9,10]. Further studies have
shown that if the mother is depressed, the child hasa three times greater risk (RR = 3.1) of developing
attention deficiency and hyperactivity disorder (ADHD)
[11,12], and almost twice the risk for both girls and chil-
dren (RR = 1.91 and RR = 2.16, respectively) of develop-
ing changes in behaviour and emotional problems [13].
There might be several possible explanations for these
findings but the most accredited one is the fact that dur-
ing pregnancy, the placenta is a major extra hypothal-
amic site for CRH production and action. In contrast to
the negative control exerted on the brain and pituitary
gland, cortisol stimulates the production of CRH in the
placenta, establishing a positive feedback loop that ter-
minates upon delivery. The fetus is therefore exposed to
high levels of glucocorticoids that affect the program-
ming of the nervous system and make the child more
prone to developing behavioural disorders [14].
Also the drug treatment of maternal depression
may have long-term consequences on the child.
Selective inhibitors of serotonin re-uptake (SSRIs)
antidepressants interfere with the hypothalamus-
pituitary-adrenal axis and with the circadian rhythms
involved in fetal development as well as with some
subtypes of serotonin receptors (5-HT-2B) respon-
sible for the development of the fetal cardiovascular
system [15,16]. For this reason, the use of paroxetine
during the first trimester of pregnancy almost dou-
bles (RR = 1.72) the risk of cardiac malformations
[17], while drugs like fluoxetine, venlafaxine, sertra-
line and citalopram showed no such effect [18].
Exposure to these drugs after the 20th week of gesta-
tion increased six-fold the newborn’s risk (RR = 6.1)
of persistent pulmonary hypertension. On the con-
trary, the use of SSRIs before the 20th week or the
use of other antidepressants, were not associated
with this risk [19]. The lung, in fact, might function
as a reservoir for antidepressants because they accu-
mulate there. Serotonin, in addition to the vasocon-
strictor effect, function as a mitogen on the smooth
muscle cells and inhibits the production of nitric
oxide, a potent vasodilator during both intra-uterine
and post-natal life [17].
Finally, exposure to SSRI antidepressants such as
fluoxetine and paroxetine increases by three times
the newborn’s risk (RR = 3) of antidepressant with-
drawal syndrome. In this case, neonates primarily
display central nervous system, motor, respiratory
and gastrointestinal signs, that are usually mild and
disappear within 2 weeks of age [20]. In fact, at the
time of birth the concentrations of long half-life
antidepressants, like paroxetine, gradually decrease.
Furthermore, the potent inhibition of serotonin re-
uptake and affinity for muscarinic receptors may be
responsible for the withdrawal syndrome and exces-
sive muscarinic stimulation [18].
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Epilepsy is a frequent neurological disorder affecting
0.4-0.8% of pregnant women. Women with epilepsy have
a higher risk of preeclampsia, gestational hypertension,
bleeding in pregnancy and excessive bleeding postpar-
tum. They also have higher incidence of congenital
anomalies and delayed cognitive development in their
children. It has been uncertain if the increased risk of
complications is due to the epilepsy per se, the use of
antiepileptic drugs, or the combination of both factors
[21]. Recent studies powerfully point to an association to
the medications and the dose used in pregnancy. The
use of anti-epileptic drugs during pregnancy has been
associated with the development of anticonvulsant
embryopathy that comprises the development of major
malformations, growth retardation and hypoplasia of the
midface and fingers. The frequency of malformations is
directly proportional to the number of drugs taken by
the mother: monotherapy almost triple (RR = 2.8) the
risk of embryopathy whereas polytherapy (taking more
than two drugs) increases the risk over four times
(RR = 4.2) [22]. Children of epileptic mothers who did
not take drugs during pregnancy had no increased
risk of embryopathy compared to controls. Therefore,
according to Cochrane’s guidelines, women with a his-
tory of epilepsy should continue medication during preg-
nancy using monotherapy at the lowest dose required to
achieve seizures control. When it’s possible, women
should avoid polytherapy (this is the practice in 40% of
women) [23]. In particular, valproate should not be used
as a drug of choice during pregnancy because it is r-
esponsible for an increased risk of impaired cognitive
function in children at 3 years of age. This risk is dose-
dependent. Therefore, valproate should not be used a
first choice medication in women of childbearing pro-
spective [24].
Type 2 diabetes
Fifteen percent of pregnant women develop impaired
glucose tolerance and more than 5% of these develop
diabetes [25]. Vigorous physical activity (7 to 13 hours
weekly) before pregnancy and light to moderate (3 to
6 hours) or vigorous exercise during pregnancy may re-
duce the risk of both impaired glucose tolerance and
diabetes mellitus in pregnancy by approximately 50%
and 30%, respectively [23]. Skeletal muscle contraction,
in fact, triggers glucose uptake and promotes insulin
sensitivity, and more intense exercise has a stronger
hypoglycemic effect [26]. Maternal hyperglycemia and
obesity, in fact, expose the fetus to hyperinsulinemia and
to a higher deposition of fat, with consequent increased
risk for developing metabolic syndrome. The risk of this
disease doubles for children born large for gestational
age (RR = 2.19), is almost double for those born to obesemothers (RR = 1.81) and then increases by one and a
half for those born to mothers with diabetes mellitus
(RR = 1.44). Thus, the relationship between prenatal
nutritional status and metabolic diseases is shaped like a
U as the risk increases at both ends of the birth weight
curve i.e. in conditions of poor nutrition and excessive
dietary intake [27]. This relationship can be clearly
showed in the population of the Pima Indians. The
Pimas successfully adapted to the desert life by elabora-
ting an irrigation system and by hunting to supplement
their cultivated crops, but by the end of the 19th century
European people disrupted their traditional agriculture
and led to important changes in their way of life. The
Pima Indians now have the world’s highest prevalence
and incidence of type 2 diabetes [28], a relative new con-
dition with 70% of 35 years old subjects with type 2 dia-
betes. The effects of the diabetic pregnancy can be
thought of as a vicious cycle. The woman with diabetes,
diagnosed before or during pregnancy, has a high-risk
pregnancy with potential complications extend well be-
yond the neonatal period. The infant of the woman with
diabetes is at high risk of becoming obese and of devel-
oping Type 2 diabetes at a young age. The young woman
whose mother had diabetes during pregnancy is at risk
of perpetuating the cycle by becoming obese and deve-
loping diabetes before or during her childbearing years
[29]. Moreover, metabolic conditions, like obesity, are
associated with a higher likelihood of autism spec-
trum disorders (OR = 1.61) and developmental delays
(OR = 2.35) [30]. In fact, in a diabetic and possibly pre-
diabetic pregnancy, poorly regulated maternal glucose
can result in adverse fetal development. Prolonged fetal
exposure to elevated glucose levels results in chronic
fetal hyperinsulinemia, with a consequent trigger to
increased oxygen consumption and metabolism, leading
to chronic intrauterine tissue hypoxia [31]. This can pro-
foundly affect neurodevelopment, including alterations
in myelination and cortical connectivity and aberrations
in hippocampal neurons [32].
Epigenetic events also play a role in determining
susceptibility to metabolic diseases. Intrauterine stres-
sors, including poor maternal nutrition and placental
dysfunction (alteration in the flow of nutrients and hyp-
oxia), may affect the development and cause epigenetic
modifications. Additional environmental factors in the
postnatal period, including accelerated postnatal growth,
obesity, inactivity and aging, further contribute to the
risk of diabetes mellitus probably through modifications
and DNA methylation in critical tissues (Figure 1) [33].
Asthma and its treatment in pregnancy
Nearly 10% of pregnant women are affected by asthma,
the disease that most commonly complicates the course




















Figure 1 Prenatal and postnatal factors contributing to the development of diabetes mellitus.
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being. Asthma exacerbations during pregnancy are asso-
ciated with low birth weight, especially in males [34];
whereas inadequate control of symptoms can lead
around an 11% incidence of preterm delivery compared
with 6% of preterm delivery in well controlled cases. The
incidence rises to over 16% if hospitalization is required.
These effects seemed independent from use of systemic
corticosteroids [35]. A pregnant mother’s poorly con-
trolled asthma is risky for both mother and fetus, much
more than the side effects of the drugs used to control
symptoms [27,36].
The use of short and long acting ß2 agonists, inhaled
corticosteroids such as budesonide [37] or oral corticoste-
roids, do not increase the risk of malformations, while the
use of chromones in pregnancy increases the incidence of
malformations of the musculoskeletal system [38].
Furthermore, one epidemiological study has shown
that forty percent of subjects presents one or more risk
factors such as: maternal or paternal asthma or asthma
during childhood, maternal smoking and respiratory
infections during childhood. Those individuals have a
higher risk of reduced forced expiratory volume in 1 sec-
ond (FEV1) between the ages of 29 and 44 years. The
presence of 3 or more of these factors increases the risk
of developing adult chronic lung disease or obstructive
pulmonary disease (COPD) sixfold for males (RR = 6.3)
and sevenfold for females (RR = 7.2) [39]. Thus, chronicobstructive pulmonary disease (COPD) find its origins in
childhood but manifest itself in adulthood. The above
factors together with cigarette smoking confer a risk of
COPD which is higher than just smoking [40].
Breathing disorders during sleep or sleep deprivation
during pregnancy
There is a number of breathing disorders during sleep,
ranging from simple snoring to severe forms of obstruct-
ive sleep apnea syndrome and obesity-hypertension.
During the third trimester, when gestational sleep
disorder breathing (SDB) is most likely to arise, the
prevalence of habitual snoring has been evaluated to be
present in between 10% and 27% of pregnant women
[41]. About 7% of women with respiratory disorders
during sleep delivers a baby small for gestational age,
with a more than threefold increased risk (RR = 3.45), or
a baby with low Apgar scores and a higher risk of mor-
tality [42]. SDB are associated with gestational diabetes
with a risk 2 to 7 times higher than the controls with
pathogenetic mechanisms depicted in Figure 2 [43,44].
The onset of hypertension is associated not only with
maternal morbidity but also with increased fetal mortal-
ity or subsequent risk of development of hypertension,
stroke, metabolic syndrome and premature death from
cardiovascular causes [45]. Furthermore, sleep disorders,
given the poor cardiopulmonary reserve of the mother


























































Figure 2 Seep disorders during pregnancy influence the risk of insulin resistence and impaired glucose tolerance.
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acidosis and fetal bradycardia [46].
Anemia in pregnancy
Anaemia of pregnancy is defined as haemoglobin (Hb)
<110 g/L or 115 g/L in some clinical practice guidelines
with a slight variation according to the trimester of preg-
nancy. However, an haemoglobin level <100 g/L denotes
anaemia at every stage during pregnancy that should be
investigated and treated because of possibly serious
effects for the mother and her baby, with an increased
risk of intrauterine growth retardation and premature
birth [47,48]. One of the most frequent causes of an-
aemia is iron deficiency [49]. Young women and particu-
larly pregnant women are at high risk for iron deficiency
[41]. Though such problem is mainly present in develop-
ing countries, it also affects a high percentage of women
of reproductive age (10-30%) in the industrialized world
[50]. Ferritin level is considered the surrogate marker for
iron deficiency, which can be classified as severe when
the serum ferritin level is below 20–30 μg/L and mild-
moderate if the serum ferritin level is below 70–100 μg/
L [40]. One of the reasons for iron deficiency, could be
the low intake of iron from the diet [51]. This problem
could be aggravated in pregnancy because during this
period iron demand is increased in order to cover the
requirements of the rise of the red cells mass, the expan-
sion of the plasma volume and to allow for the growth
of the feto-placental unit [52]. Generally, iron deposits
derived from the mother are exhausted within the first
6 months of life, after which the child must begin to
produce iron independently. Although in some casesbabies born to mothers with anemia may have normal
levels of iron, because of active placental iron transport;
however levels are typically lower than infants born to
mothers without anemia. It has been shown that precon-
ceptional [53] and early pregnancy anaemia [54] are
associated with an increased risk of low birth weight,
birth length and head circumference. Several mechan-
isms have been proposed to clarify the pathways through
which iron deficiency and anemia could weaken fetal
growth. Iron deficiency and hypoxia resulting from
anemia can induce maternal and fetal stress thus in-
creasing norepinephrine concentration. The stress, in
turn, activates the production of corticotrophin-releasing
hormone which stimulates fetal cortisol. As a result, lon-
gitudinal growth of the fetus could be impaired by the
action of cortisol. Another possible explanation is that
iron deficiency causes oxidative damage on erythrocytes
and the feto-placental unit. Iron deficiency can also in-
crease the risk of maternal infections, which can stimu-
late the production of CRH and are a major risk factor
for preterm delivery [55].” Moreover, offspring of mother
with anemia had doubled risk of wheezing (OR = 2.42)
and more than triple the risk of current asthma at the
age of six years (RR = 3.46) [56]. On the basis of such
evidences, the fact that low to moderate dose iron sup-
plementation in early pregnancy benefits fetal growth in
women with iron deficiency is not surprising. The
recommended daily dietary allowance for iron in
pregnancy is 27 mg instead of 8 mg in the adult non
pregnant population. Lactation requires a daily dietary
allowance of 10 mg [57,58]. The positive effect on fetal
growth could be explained by a preferential transfer of
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other micro-nutrients such as selenium, vitamins E, D
and C, zinc and folic acid is responsible for the onset of
disorders affecting the respiratory system in the off-
spring [46].
Maternal lifestyle and environment
Maternal behaviour, interpersonal stress and psychosocial
trauma
Maternal behaviour during early periods of life can alter
the epigenetic state of the fetal DNA. Studies in mouse
models have shown that infants rats whose mother had
a high frequency of “licking, grooming and arched-back
nursing” are able to better react to stress [59]. Maternal
care during infancy regulates the development of neural
systems mediating the expression of fearfulness in the
rat. In fact, it has been showed an increased hippocam-
pal expression of the glucocorticoid receptor mRNA and
protein, a decreased hypothalamic corticotropin release
factor and reduced hypothalamic-pituitary-adrenal re-
sponse to stress in pups born from mothers with licking,
grooming and arched-back nursing behaviour [60,61].
Maternal stress and maternal-placental-fetal biological
mediators of stress can affect fetal development. In fact
it has been showed that exposure to maternal psycho-
social stress during intrauterine life is associated with
significantly shorter leukocyte telomere length in young
adulthood, a predictor of age related disease onset and
mortality [62]. This provides a biological basis for specu-
lation about the effects of early occurrence of poverty
and how exposure to abuse, family conflict, emotional
neglect and severe discipline could lead to individual dif-
ferences in the nervous and endocrine response to stress
and increase susceptibility to common adult disorders
such as depression, anxiety, drug abuse or chronic dis-
eases like diabetes, cardiovascular disease and obesity.
Moreover, stress during pregnancy is associated with
the risk of delivering a preterm baby or a child small for
gestational age [63,64] and it contributes to less control
of the parasympathetic system on heart rate, with a low
heart rate variability in response to stressful stimuli [65].
In a study it has been shown that prenatal anxiety and
stress predicted a substantial amount of variance in in-
fant diseases and antibiotic use and precisely 9.3% for re-
spiratory, 10.7% for general, 8.9% for skin, and 7.6%
antibiotic use [66]. Moreover, maternal stress during
pregnancy alters the cytokine response of the innate and
adaptive immune system. If on the one hand high levels
of IL-8 and TNF-α in response to microbial stimuli are
observed, on the other, there is a reduction in levels of
IFN-γ with an increase in IL-13. This generates an
obvious imbalance of the immune response in favour of
Th2 lymphocytes and susceptibility to allergic diseases
[67,68]. An association between prenatal stress andimmune function in human adults has been documen-
ted. Peripheral blood mononuclear cells from healthy
young women whose mothers experienced major nega-
tive life events during their pregnancy (Prenatal Stress,
PS group), and from a female comparison group, were
stimulated with phytohemagglutinin (PHA), and subse-
quent cytokine production was measured. A bias for
T-helper 2 (Th2) cytokine production due to an overpro-
duction of IL-4 relative to IFN-gamma after PHA stimu-
lation was observed in PS subjects. In addition, IL-6 and
IL-10 were also significantly elevated suggesting a direct
association between prenatal stress exposure and altera-
tions in immune parameters in adult women [69]. In
fact, children whose mothers experienced interpersonal
violence and trauma during pregnancy have twice the
risk of developing asthma during their childhood [70].
Exposure to maternal stress also affects the child’s cog-
nitive performance such as language, comprehension and
reasoning, all of them principally realized in the prefrontal
cortex. This brain region is known to develop later in term
of myelination and synaptic density. Because of its pro-
tracted development and the expression of glucocorticoid
receptors, the prefrontal cortex may be prone to early
insults. Since children exposed to high levels of hydrocor-
tisone have longer time reactions, this could provide sup-
port for an association between prenatal stress exposure
and the potential modulatory effect of cortisol on the
working memory performance, which may reflect com-
promised development of the prefrontal cortex [71].
Finally, prenatal stress increases the future risk of insu-
lin resistance, with higher levels of insulin and C-peptide
than in controls as well as a lipid profile compatible with
the development of metabolic syndrome [72].
Smoking in pregnancy
Cigarette smoke contains more than 4000 compounds,
including polycyclic aromatic hydrocarbons such as ari-
lamine and N-nitrosamines. The ability of the individual
to convert these substances into less toxic compounds is
important to minimize their adverse effects. This is
made possible by enzymes that allow the metabolism
and detoxification of these substances. Enzymes such as
CYP1A1 and glutathione-S-transferase (GSTT1), im-
portant for the detoxification of the compounds, are
involved in this process. Polymorphisms of these genes
have been associated with a reduction in birth weight of
between 250 g and 600 g [73], with a higher risk of deli-
vering a baby of low birth weight (< 2500gr) (RR = 1.32)
or small for gestational age (RR = 1.21) [74], and a linear
dose–response relationship between exposure and sec-
ond trimester femur growth was observed with almost
1 cm lower femur growth for the highest versus the low-
est tertile of exposure [75]. However, the side effects of
smoking may be reversible in early pregnancy because
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tion have a lesser probability of having a premature baby
or one small for gestational age, which is not different
from that of non-smoking women, 4% and 10%, respec-
tively. Conversely, if a woman continues to smoke, the
incidence of preterm birth is around 10% and the risk of
having a baby small for gestational age raises at 17%
[76]. Furthermore, children exposed to cigarette smoke
continue to have respiratory problems during childhood,
with twice the risk (RR = 2.18) of having lower values of
FEV1 [75]. In a systematic review and meta-analysis it
has been shown that exposure to pre- or postnatal pas-
sive smoke exposure was associated with a 30% to 70%
increased risk of incident wheezing (strongest effect
from postnatal maternal smoking on wheeze in children
aged ≤ 2 years, OR = 1.70) and a 21% to 85% increase in
incident asthma (strongest effect from prenatal mater-
nal smoking on asthma in children aged ≤ 2 years,
OR = 1.85) [77]. Maternal smoking during pregnancy
leads to abnormal lung function in infancy that tracks
through to later childhood and continues into adult life.
This is associated with transient wheezing illnesses
through early childhood and increases the risk of
chronic obstructive pulmonary disease in the elderly
[78]. Also passive exposure of pregnant women to ETS
may lead to asthma in their offspring: passive exposure
to ETS, mainly during the third trimester of pregnancy,
was significantly associated with asthma- and allergy-
related symptoms after adjusting for several confounders
in a multivariate analysis (current wheeze: OR = 1.42,
pruritic rash ever: OR = 1.45). As a consequence public
health policies should be oriented not only towards
smoking cessation, but also reinforce elimination of ETS
exposure of pregnant women [79]. In brief, exposure to
passive smoking increases the incidence of wheeze and
asthma in children and young people by at least 20%.
Preventing parental smoking is crucially important to
the prevention of asthma. Nicotine, in fact, causes higher
placental vascular resistance, decreases blood flow in the
uterus, and increases the concentration of carboxy-
haemoglobin, all factors responsible for chronic hypoxia
and reduced fetal development [80]. In addition, chil-
dren of smoking mothers have a higher risk (RR = 1.5) of
being overweight or obese [81,82] because nicotine with-
drawal promotes overeating and weight gain, and on the
other, children born from smoking mother tend to get
less exercise and have a lower quality diet [74].
Children exposed to tobacco smoke during pregnancy
also have a higher risk of poor neurodevelopmental
outcome [80]. In a prospective follow-up study of infants
with a birth weight ≤ 1500 g or a gestational age <
32 weeks, the brain was imaged by serial brain ultra-
sound examinations until discharge and magnetic reson-
ance imaging at term age and it has been found that thefrontal lobe (P = 0.01) and the cerebellar (P = 0.03)
volumes were significantly smaller in the exposed than
in the unexposed infants [83]. This is consistent with
reports showing an association between prenatal smok-
ing exposure and impairments in frontal lobe and cere-
bellar functions such as emotion, impulse control, and
attention. Effectively, these children have a more than
doubled risk of developing attention deficit disorder and
hyperactivity disorder (ADHD) (RR = 2.5) [84,85] com-
pared to babies born to non-smoking mothers. Genes re-
lating to the dopaminergic pathways are the focus of
most genetic studies of AHD. The gene for the dopa-
mine transporter (DAT) is of particular interest because
is the site of action of psychostimulants. It has been
shown that homozygosis for this gene and exposure to
cigarette smoke during pregnancy increase the risk of
developing ADHD and determine a poor response to
psychostimulants [86]. This risk is approximately three
times greater when the gene for the dopamine trans-
porter DAT1 and subtype D4 for the dopamine receptor
DRD4 is inherited (RR = 2.9 and RR = 3, respectively) but
inheriting both alleles increases by 9-fold the risk of
ADHD (RR = 9) [79].
The role of the home
The home is the place where children spend most of
their time, estimated at 15 hours out of 24 [87]. Given
the stable increase in the incidence of asthma among
children, it is important to pay attention and implement
environmental measures in the home to help prevent it.
Contact with synthetic textiles should be avoided in the
first ages of life: during the first months of life sleeping
in synthetic sleeping bags increases by more than 4
times the risk (RR = 4.33) of wheezing at the age of seven
years [88]. Furthermore, the use of synthetic pillows
doubles the risk (RR = 2.5) of wheezing and the risk rises
to more than five times (RR = 5.2) when both synthetic
pillows and blankets are used [89]. Synthetic materials,
in fact, have a structure that allows the accumulation of
high concentrations of dust mite allergen (Der p1), even
15 times higher compared to cotton fabrics [90]. Fur-
thermore, synthetic pillows contain significantly more
pet allergens than feather pillows, supporting the view
that tightly woven encasements surrounding feather pil-
lows act as a barrier for allergens [91].
In addition, chemicals used for cleaning are respon-
sible for increasing domestic pollution and more than
doubling the risk of wheeze (RR = 2.3), [92] and they
cause a decrease in FEV1 and FEF25-75 [93]. This derives
from both a detrimental effect on the development of
airways in the prenatal period (epigenetic effect?) but
also from the effects in the post-natal period. In particu-
lar, this association was noted for the use of cleaning
sprays [85] that contain active ingredients such as
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sodium hydroxide (caustic soda), acrylic polymers and
terpenes [94]. When sprayed on surfaces to be cleaned,
these compounds enter easily into the airways, irritating
them [86].
The role of environmental pollution
In New York City it has been shown that prenatal ex-
posure to pollutants doubles the risk of delivering an in-
fant small for gestational age and increases by five times
the risk of preterm delivery [95]. These effects were
observed in African-American but not in Domenicans
and this may reflect modification of the risk by healthful
cultural practice among Domenican immigrants includ-
ing diets with higher nutritional quality and greater so-
cial support. In the same environment it has been
reported that infants of pregnant women exposed to
high concentrations of polycyclic aromatic hydrocarbons
have more than twice the risk of developing cognitive
delay at age three, resulting in poor school performance
and low IQ at age 5. Furthermore, forty percent of the
analyzes on the DNA of white blood cells of umbilical
cord blood of New York City children showed damage
to the DNA reflecting transplacental exposure to traffic-
related polycyclic aromatic hydrocarbons (PAHs). The
increased formation of DNA adducts is associated with a
possible consequent increased risk in adulthood of can-
cer [96] and of asthma [97]. At this regard it has been
shown that for concentrations of 2.41 ng/m3 of PAHs
the risk of finding methylation in the DNA increases by
almost 14 times (RR = 13.8) and the risk of developing
asthma increases by almost four times (RR = 3.9). Con-
cerns about pollutants were always related to elderly
people and respiratory diseases, but now we start to
understand that fetal tissues are exposed as well with
long time persistent consequences. Based on these
observations, the reduction of environmental pollutants,
mostly from vehicle fuel combustion, could help reduce
the incidence of several diseases.
Dietary recommendations
A pregnant mother’s diet has both an immediate pro-
tective effect, and a long lasting effect on life. We have
discussed the fact that exposure to pollutants like PAHs
increases the risk of mutations, with DNA adduct for-
mation and carcinogenesis. However it has been shown
that antioxidants protect against damage caused by these
substances. Subjects with low levels of alpha tocopherol
have an almost four times higher risk (RR = 3.96) of hav-
ing high levels of DNA adducts than those with high
levels of antioxidants [98]. Also fish consumption during
pregnancy contributes to reduce the risk of low birth
weight [99], preterm birth (<34 weeks), the number of
low birth weight babies and the number of admissionsto neonatal intensive care [100]. Other studies demon-
strated the protective role of fish against the development
of atopic dermatitis at the age of one year and asthma at
six years, with a decrease of 30% and 50% in the incidence
of these allergic diseases, respectively [101].
It has been reported that women who consumed high
amounts of fish during pregnancy had a lower incidence
of postpartum depression during the first six months
after delivery (9.67% vs. 11.19% of women with low in-
take), while not all authors agree on the protective role
on the development of the brain and cognitive functions
[92,102]. Fish is an important source of polyunsaturated
fatty acids (docosahexaenoic acid DHA-EPA-and acid-
eicosaepentanoic-) and essential nutrients that are not
produced by the human body, and which play a protect-
ive role in the development of the neurological, immune
and cardiovascular systems. They are essential for the
development of the brain and retina, tissues that have
the maximum uptake of these substances during the sec-
ond half of pregnancy and early in childhood. However,
not all types of fish can be consumed during pregnancy,
because in some kind of fish the content of mercury is
higher. Salmon, shrimp and hake are recommended be-
cause they are rich in ω-3 fatty acids and low in mer-
cury, whereas large deep-water fish like tuna, swordfish
and Atlantic shark should be avoided [103,104]. Small-
sized fish, like sardines can be consumed because of
their high content of selenium, an element capable of re-
ducing the toxicity of mercury [105].
A pregnant mother’s diet that includes fruits and vegeta-
bles can also prevent asthma and atopic dermatitis [106].
Furthermore, levels of maternal vitamin E affect the deve-
lopment of fetal biometrics (crown-rump length, femur
length and biparietal diameter) and lung development: for
every millimeter of increase in fetus length, there is an
increase of up to 5 ml of FEV1 and 6 ml of FVC [107].
Intake of vitamin D during pregnancy, either through the
diet or through supplements, has a protective role against
asthma and atopic dermatitis. High levels of maternal vita-
min D can reduce the risk of asthma and wheezing in chil-
dren by up to 60% [108,109]. The average dose of vitamin
D to be taken is about 600 UI/day [110], but many studies
indicate that a higher dose of vitamin D during pregnancy
and lactation, up to 1000 UI/day, is necessary to achieve a
good level of vitamin D assets [111].
Finally, maternal cholesterol levels below the 10th per-
centile (<159 mg/dl) and higher than the 90th (261 mg/
dl) are associated with an increased risk of preterm
delivery. Children born at term to mothers with low
levels of cholesterol weigh about 150 grams less than
controls, and have a higher risk of microcephaly [112].
Cholesterol Low-density lipoprotein (LDL) represents the
main substrate for the synthesis of progesterone and cell
membranes of the decidua, essential for proper installation
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tal cholesterol concentrations cause changes in placental
transport functions and fetal growth retardation [104].
Folic acid and pregnancy
According to the U.S. Preventive Services Task Force all
women of childbearing age or who are planning to become
pregnant should take daily supplements of folic acid, at a
dose range between 0.4 and 0.8 mg, to prevent neural tube
defects. Several studies provide evidence that specific genes
and DNA methylation sites are subject to change during
development and during a lifetime as a direct response to
nutrition. Studies of the methyl donors-folate, choline, and
methionine offer the most convincing evidence of a role in
mediating DNA methylation changes [113]. Folic acid is
essential for the synthesis and function of DNA and affects
the embryogenesis of the nervous system [114]. Since a re-
quirement for folic acid intake during pregnancy was intro-
duced, there has been a 19% reduction of neural tube
defects (anencephaly and bifid spine). However, only about
35% of women of childbearing age take the minimal daily
dose of folic acid, and annual consumption of folic acid is
decreasing [115]. Supplementation with acid folic decreases
the incidence of the risk of preterm delivery in the period
20-28th week of gestation by 70% and by 50% during the
28-32nd week period; but has no influence on the labor
thereafter. In fact, low concentrations of folic acid can alter
the function of lymphocytes and neutrophils, increasing
the risk of bacteriuria in pregnancy, which in turn can in-
crease the risk of preterm delivery [116].
Conclusions
Studies in both animal and human models have shown that
exposure to particular events during the critical stages of
pregnancy can alter the expression of genes in the fetus.
This leads to changes that may persist throughout life
causing increased susceptibility to disease. Adverse events
that lead to embryonic, fetal or neonatal epigenetic changes
are responsible for altering the mechanisms of growth and
metabolism observed later in childhood. The health of the
child and issues that will determine its appetite and metab-
olism, intelligence and temperament in life depend on the
type and amount of nutrients that the baby receives in the
womb, pollution, drugs and infections which it is exposed
to before and after birth, the mental and physical health of
the mother and her levels of stress and mental illness.
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